Memantine Improves Safety of Thrombolysis for Stroke | Zendy

Axel Montagne | Zendy; Marie Hébert | Zendy; Amandine Jullienne | Zendy; Flavie Lesept | Zendy; Audrey Le Béhot | Zendy; Morgane Louessard | Zendy; Maxime Gauberti | Zendy; Cyrille Orset | Zendy; Carine Ali | Zendy; Véronique Agin | Zendy; Eric Maubert | Zendy; Denis Vivien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Memantine Improves Safety of Thrombolysis for Stroke

Author(s) -

Axel Montagne,

Marie Hébert,

Amandine Jullienne,

Flavie Lesept,

Audrey Le Béhot,

Morgane Louessard,

Maxime Gauberti,

Cyrille Orset,

Carine Ali,

Véronique Agin,

Eric Maubert,

Denis Vivien

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.669374

Subject(s) - memantine , medicine , neuroprotection , stroke (engine) , thrombolysis , intracerebral hemorrhage , tissue plasminogen activator , pharmacology , anesthesia , neurotoxicity , excitotoxicity , nmda receptor , receptor , toxicity , mechanical engineering , myocardial infarction , subarachnoid hemorrhage , engineering

Despite side effects including N-methyl-d-aspartate-mediated neurotoxicity, recombinant tissue-type plasminogen activator (rtPA) remains the only approved acute treatment for ischemic stroke. Memantine, used for treatment of Alzheimer disease, is an antagonist for N-methyl-d-aspartate receptors. We investigated whether memantine could be used as a neuroprotective adjunct therapy for rtPA-induced thrombolysis after stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research